MYL(SH:600993) Zheng Quan Zhi Xing·2025-08-29 16:40Core Viewpoint - The board of directors of Mayinglong Pharmaceutical Group Co., Ltd. approved the 2025 semi-annual report and the remuneration plans for directors and senior management during the 21st meeting of the 11th board session held on August 27, 2025 [1][2]. Group 1: 2025 Semi-Annual Report - The 2025 semi-annual report was approved with unanimous support from the board members, indicating a strong consensus on the report's content [1]. Group 2: Remuneration Plans - The independent directors will receive a fixed annual allowance of 180,000 yuan (including tax), paid monthly [2]. - Non-independent directors not involved in daily management will receive a fixed annual allowance of 120,000 yuan (including tax), also paid monthly [2]. - The remuneration for non-independent directors and senior management involved in daily operations will consist of a basic salary and performance-based pay, determined by their roles and the company's annual performance assessment [2].